drugset / Trial / NCT01219413
Influence of Aliskiren on Proteinuria
RandomizedCrossoverDouble-blindTreatment
Summary
To evaluate the proteinuria lowering efficacy as well as tolerability and safety of the renin inhibitor aliskiren compared with that of placebo and angiotensin converting enzyme inhibitor perindopril in patients with non-diabetic chronic renal disease.
Timeline
- Start
- 2009-03
- Primary completion
- 2010-07
- Completion
- 2010-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aliskiren | Small molecule | 300 mg | Oral |
| Subject | Perindopril | Small molecule | 10 mg | — |